Hims & Hers Health, Inc. (NYSE:HIMS) Receives $31.43 Average Price Target from Analysts

Shares of Hims & Hers Health, Inc. (NYSE:HIMS) have been assigned an average recommendation of “Hold” from the sixteen ratings firms that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, eleven have assigned a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $32.4333.

Several equities research analysts recently issued reports on the stock. Zacks Research raised shares of Hims & Hers Health from a “strong sell” rating to a “hold” rating in a research report on Monday, July 13th. Jefferies Financial Group set a $24.50 price target on shares of Hims & Hers Health in a research note on Tuesday, May 12th. Weiss Ratings reiterated a “sell (d)” rating on shares of Hims & Hers Health in a report on Friday, August 7th. Barclays boosted their price objective on shares of Hims & Hers Health from $29.00 to $39.00 and gave the company an “overweight” rating in a research note on Wednesday, June 17th. Finally, Canaccord Genuity Group upped their price objective on Hims & Hers Health from $32.00 to $40.00 and gave the stock a “buy” rating in a report on Wednesday, July 1st.

Key Stories Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Second-quarter revenue increased 38.2% year over year to $753.2 million, exceeding analysts’ expectations of approximately $699 million. Subscriber growth, AI-driven engagement, specialty care and international expansion supported the performance. Management also raised its 2026 revenue outlook. Hims & Hers Q2 revenue beat offset by wider-than-expected loss
• Positive Sentiment: Needham raised its price target from $35 to $42 and maintained a Buy rating, indicating that some analysts believe current valuation reflects much of the near-term weakness and that investments could support longer-term growth.
• Neutral Sentiment: Hims plans to offer certain legally available compounded peptides in 2026. However, analysts cited by Reuters expect the new offering to contribute little revenue this year, making it more of a longer-term opportunity than an immediate catalyst. As Hims prepares for peptides launch, Wall Street cautious on prospects this year
• Negative Sentiment: The company reported a $0.37-per-share quarterly loss, substantially worse than the expected $0.05 loss. Gross-margin compression and negative free cash flow—partly tied to the shift toward branded GLP-1 weight-loss drugs, restructuring and international expansion—overshadowed the revenue beat and guidance increase. Hims & Hers shares slide as costly weight-loss push squeezes margins
• Negative Sentiment: Multiple law firms announced investigations into potential securities-law violations, fiduciary-duty breaches, data-sharing practices, billing and subscription-cancellation policies. The FTC and consumer plaintiffs have also pursued legal action. These announcements increase uncertainty around potential costs, liabilities and reputational damage, although they represent allegations rather than findings of wrongdoing. Berger Montague investigation
• Negative Sentiment: Wall Street remains cautious: Morgan Stanley highlighted pressure from gross margin and free cash flow, while Citi lowered its target to $33 and kept a Neutral rating. The stock’s decline reflects concern that higher revenue is not yet translating into sustainable earnings.

Hims & Hers Health Stock Performance

NYSE HIMS opened at $29.83 on Friday. The business’s 50-day moving average price is $32.06 and its 200 day moving average price is $26.08. The company has a current ratio of 1.69, a quick ratio of 1.56 and a debt-to-equity ratio of 2.18. Hims & Hers Health has a twelve month low of $13.74 and a twelve month high of $65.30. The company has a market capitalization of $6.90 billion, a PE ratio of -47.35, a price-to-earnings-growth ratio of 85.86 and a beta of 2.40.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings results on Monday, August 10th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.32). Hims & Hers Health had a negative net margin of 5.51% and a negative return on equity of 5.89%. The business had revenue of $753.21 million during the quarter, compared to analysts’ expectations of $698.90 million. During the same quarter last year, the firm earned $0.17 EPS. The firm’s quarterly revenue was up 38.2% compared to the same quarter last year. On average, research analysts predict that Hims & Hers Health will post 0.03 earnings per share for the current year.

Insider Transactions at Hims & Hers Health

In other Hims & Hers Health news, COO Michael Chi sold 14,027 shares of the company’s stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $31.50, for a total transaction of $441,850.50. Following the completion of the sale, the chief operating officer directly owned 432,124 shares in the company, valued at $13,611,906. This represents a 3.14% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director David B. Wells acquired 48,400 shares of the business’s stock in a transaction dated Tuesday, May 26th. The stock was purchased at an average price of $24.23 per share, for a total transaction of $1,172,732.00. Following the completion of the acquisition, the director owned 224,417 shares in the company, valued at approximately $5,437,623.91. This trade represents a 27.50% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have sold 83,126 shares of company stock valued at $2,711,339 in the last ninety days. Company insiders own 11.76% of the company’s stock.

Institutional Trading of Hims & Hers Health

Institutional investors have recently modified their holdings of the company. Versant Capital Management Inc lifted its position in Hims & Hers Health by 801.2% during the second quarter. Versant Capital Management Inc now owns 748 shares of the company’s stock valued at $26,000 after buying an additional 665 shares in the last quarter. MassMutual Private Wealth & Trust FSB grew its stake in Hims & Hers Health by 70.0% during the second quarter. MassMutual Private Wealth & Trust FSB now owns 775 shares of the company’s stock worth $27,000 after buying an additional 319 shares during the period. Flagship Harbor Advisors LLC acquired a new stake in shares of Hims & Hers Health in the fourth quarter worth $28,000. Binnacle Investments Inc purchased a new position in shares of Hims & Hers Health in the 3rd quarter valued at $28,000. Finally, Bogart Wealth LLC raised its stake in shares of Hims & Hers Health by 235.8% in the 4th quarter. Bogart Wealth LLC now owns 900 shares of the company’s stock valued at $29,000 after acquiring an additional 632 shares during the period. Hedge funds and other institutional investors own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.